Skip to content

Study · Measured the body's own peptide · 1997

5 results

Comparison between vasoactive intestinal polypeptide and pituitary adenylate cyclase activating polypeptide levels in neuroblastoma tumour tissues.

Vertongen P, De Clerck P, Fournet JC, Martelli H, Hélardot P, Devalck C, Peeters T, Sariban E, Robberecht P

Neuropeptides1 Oct 1997Cited by 12 (Europe PMC)

PMID9413016 (opens in a new tab)DOI10.1016/s0143-4179(97)90033-0 (opens in a new tab)PepBankPUB-09413016
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    VIP mRNA and VIP were detected in 9 of 12 neuroblastoma tumours.

    In plain wordsThe body's own VIP was found in 9 of 12 neuroblastoma tumour samples.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableVIP expression in neuroblastoma tumours
    Study

    n = 12

    Outcome group
    Endogenous peptide levels · Cancer

    Measurements

    Tumours with VIP detected
    9 of 12 tumours

    Source sentences

    Summary
    VIP mRNA and VIP were detected in 9/12 tumours.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    Neuroblastoma tumours with the highest VIP levels also had the highest PACAP contents.

    In plain wordsNeuroblastoma tumours with the most of the body's own VIP also had the most PACAP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableVIP and PACAP content in neuroblastoma tumours
    Study

    n = 12

    Outcome group
    Endogenous peptide levels · Cancer

    Source sentences

    Summary
    The tumours having the highest VIP levels also had the highest PACAP contents

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelObservational studyOther

    Neuroblastoma tumours with the highest VIP levels were associated with a watery diarrhoea syndrome.

    In plain wordsNeuroblastoma tumours with the most of the body's own VIP were linked to a watery diarrhoea syndrome.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableTumour VIP level and watery diarrhoea syndrome
    Study

    n = 12

    Outcome group
    Endogenous peptide levels · Gastrointestinal

    Source sentences

    Summary
    and were associated with a watery diarrhoea syndrome due to activation of intestinal VIP receptors.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

Studies that did not test the peptide alone2

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 04HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneObservational studyMechanism

    VIP receptor mRNA was expressed in 5 of 12 neuroblastoma tumours.

    In plain wordsThe genetic message for the VIP receptor was found in 5 of 12 neuroblastoma tumour samples.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableVIP receptor mRNA expression in neuroblastoma tumours
    Study

    n = 12

    Outcome group
    Receptor activity and mechanism · Cancer

    Measurements

    Tumours with VIP receptor mRNA
    5 of 12 tumours

    Source sentences

    Summary
    VIP receptor mRNA was expressed in 5/12 tumours

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 05HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneObservational studyMechanism

    Functional VIP receptors were never demonstrated in the neuroblastoma tumours.

    In plain wordsWorking VIP receptors were never shown in the neuroblastoma tumour samples.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeFunctional VIP receptors in neuroblastoma tumours
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    functional VIP receptors were never demonstrated.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.